EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study

Shih-Chieh Chang, Yu-Feng Wei, Chung-Yu Chen, Yi-Chun Lai, Po-Wei Hu, Jui-Chi Hung, Cheng-Yu Chang iD

Molecular Diagnosis & Therapy · 2024

DOI: 10.1007/s40291-024-00736-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Molecular Diagnosis & Therapy, 2024. Verfasst von Shih-Chieh Chang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Chest Medicine, Department of Internal Medicine, National Yang Ming Chiao Tung University Hospital, Yi-Lan, Taiwan. Hauptthemen laut MEDLINE: Pleural Effusion, Malignant, Mutation, High-Throughput Nucleotide Sequencing, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Comprehensive next-generation sequencing (NGS) of non-small-cell lung cancer specimens can identify oncogenic driver mutations and their corresponding targeted therapies. Plasma cell-free DNA (cfDNA) genotyping is easy to perform; however, false negatives cannot be overlooked. We explored malignant pleural effusion (MPE), a rich source of cfDNA, as a non-inferior alternative to tumor tissues for genotyping. METHODS: We conducted a prospective trial including 39 patients with newly diagnosed stage IV lung adenocarcinoma who presented with MPE. Tissue tests matching hotspot variants, including EGFR, ALK, and ROS1, were compared with the AlphaLiquid100 of PE-cfDNA. RESULTS: Among the 39 PE-cfDNA samples successfully sequenced, 32 (82.1%) had a PE cell-block tumor content of < 10%. Standard tissue or cell-block testing for EGFR, ALK, and ROS1 identified 20 mutations (51.3%), whereas PE cfDNA identified 25 mutations (64.1%). Five EGFR mutations were observed in PE cfDNA but not in Cobas EGFR owing to coverage or insufficient tumor content issues. The overall rate of oncogenic mutations identified in the PE cfDNA was 92.3%, and the mutation distribution was as follows: even with a very low cfDNA input, high detection rates could be achieved. Otherwise, most patients harbored co-mutations. Comparison of pleural fluid NGS with traditional testing revealed differences in accuracy. We also followed up with patients with EGFR-sensitizing mutations who had a treatment response rate of 97.2% after 3 months. CONCLUSIONS: Genotyping of MPE supernatant cfDNA is feasible in clinical practice, in addition to plasma and tumor testing, to improve diagnostic yield and extend patients' benefit from targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pleural Effusion, MalignantMutationHigh-Throughput Nucleotide SequencingLung NeoplasmsNeoplasm StagingHumansFemaleMiddle AgedMaleAgedProspective StudiesCell-Free Nucleic AcidsBiomarkers, TumorAdultAged, 80 and overAdenocarcinoma of LungCirculating Tumor DNAErbB Receptors

Substanzen

Cell-Free Nucleic AcidsBiomarkers, TumorCirculating Tumor DNAErbB Receptors

Autor:innen und Institutionen

  • Division of Chest Medicine, Department of Internal Medicine, National Yang Ming Chiao Tung University Hospital, Yi-Lan, Taiwan.
  • School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
  • Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan.
  • Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan. koala2716@gmail.com.

ORCID-Profile: Cheng-Yu Chang

Zitieren

APA

Chang, S. C., Wei, Y. F., Chen, C. Y., Lai, Y. C., Hu, P. W., Hung, J. C., & Chang, C. Y. (2024). Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study. Molecular Diagnosis & Therapy. https://doi.org/10.1007/s40291-024-00736-8

Vancouver

Chang SC, Wei YF, Chen CY, Lai YC, Hu PW, Hung JC, et al. Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study. Molecular Diagnosis & Therapy. 2024. doi:10.1007/s40291-024-00736-8

BibTeX
@article{Chang2024,
  author = {Chang, Shih-Chieh and Wei, Yu-Feng and Chen, Chung-Yu and Lai, Yi-Chun and Hu, Po-Wei and Hung, Jui-Chi and Chang, Cheng-Yu},
  title = {Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study},
  journal = {Molecular Diagnosis & Therapy},
  year = {2024},
  doi = {10.1007/s40291-024-00736-8}
}
Kostenlos starten →